制作実績

ANTINEOPLASTON anticancer substance in the human body

became involved in the Antineoplaston research and what it learned about  the potential role of Antineoplaston in cancer treatment and It further learned the social aspect of cancer during the basic and clinical research.

ジャンル
医学・薬学 からだ・メンタルヘルス
シリーズ
電子書籍のみ 新刊
著者
・著 津田英照・著 つだひであき・著
ISBN
判型
109ページ
出版年月日
価格
1320円(税込)

目次

Preface
Chapter 1 What is cancer?
Chapter 2 Clinical practice in cancer
Chapter 3 Antineoplaston -Basics-
Chapter 4 Clinical trials of Antineoplaston A10 and AS2-1 in Japan
Chapter 5 Social aspect of cancer
Chapter 6 Lessons learned from our Antineoplaston research
Epilogue

内容紹介

Cancer is a genetic disease. Many abnormalities in genes, epigenetics
and gene products are involved in the formation and growth of cancer.

Cancer is diverse, one cancer may differ genetically from other cancers though they may look same.

Dr. Burzynski discovered Antineoplaston in the human body. It trans substantiate anticancer effect by a unique multi-molecular targeted mode which is quite different from conventional cancer drugs. This raised doubt and confusion in the medical field in USA.

Cancer is a social problem and anybody can have it.
The number of cancer patients increases as society ages.
Over 600,000 people died from advanced cancer in the USA while in Japan it was 370,000 in 2018. Advanced cancer patients eagerly anticipate the arrival of an effective treatment.

An advanced treatment technology is effective but expensive. It is an excessive financial burden for both the individual and the state.

This book describes how the Kurume University, School of Medicine, Japan
became involved in the Antineoplaston research and what it learned about
the potential role of Antineoplaston in cancer treatment and It further learned the social
aspect of cancer during the basic and clinical research.

■著者紹介

Hideaki Tsuda MD(津田英照 つだひであき)

Hideaki Tsuda M.D. was born in 1942.
He graduated from Kurume University School of Medicine in 1969.
He studied abroad in Baylor College of Medicine, Houston Texas, USA from 1970 to 1973.
He formed Antineoplaston Study Group in Kurume University in 1985 and had been involved in the basic and clinical research of Antineoplaston since then.
He became Professor in Kurume Medical Center in 2000.
He was the director of Kurume Daiichi Social Insurance Hospital from 2002 to 2012. He has been the adviser of JCHO Kurume General Hospital since 2016.

テキストのコピーはできません。